SEC Tracker
Get the app

Artiva Biotherapeutics ARTV

Fred Aslan (ARTV) reports stock sale.

Fred Aslan, insider filing for ARTV

Form
4
Filed
Importance
Routine
  1. Oct 6, 2026 - Sale of 23,463 shares
  2. Sale price: $7.1977
  3. Reporting person: Fred Aslan, CEO

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Artiva Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  2. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  3. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  4. Pluri PLUR public float $15M, Dec 31, 2025
  5. CalciMedica CALC public float $16M, Jun 30, 2025